News | May 29, 2015

Public-Private Partnership Restarting Mo-99 Production in U.S.

Cooperative R&D agreement will develop scalable standalone system for domestic production

May 29, 2015 — National Security Technologies LLC (NSTec) and Henderson, Nevada-based Global Medical Isotope Systems (GMIS) announced a public-private partnership agreement for research and development of an essential radioactive isotope used in millions of medical diagnostic imaging procedures annually.

Known primarily as the management and operations contractor for the Nevada National Security Site (NNSS), NSTec is leveraging its traditional national security role with the signing of its first cooperative research and development agreement (CRADA). The agreement describes NSTec's technical integration, modeling, materials and design support to GMIS's mission in the development and deployment of a ground-breaking approach to the production of the radioactive isotope molybdenum-99 (Mo-99).

By introducing a safe, decentralized, on-demand production system using non-enriched uranium, the two companies are answering a critical supply need of the medical imaging community. The United States terminated its domestic Mo-99 production in the 1990s, but continues to import the isotope from Canada and Europe. In addition, U.S. and global demand for Mo-99 has grown substantially in recent years, making easy and timely access to supplies of the isotope more important than ever.

The imaging isotope Technetium-99m (Tc-99m) is a decay by-product of Mo-99, and has a half-life of only about 6 hours. This unique physical characteristic makes Tc-99m the most widely used medical diagnostic isotope in nuclear medicine. Its short half-life allows it to be used in body-scanning procedures that collect data rapidly, but keeps total patient radiation exposure low — but it also makes keeping an inventory next to impossible. 

Presently, there are about 40 million imaging and diagnostic procedures performed worldwide per year, of which 80-85 percent use Tc-99m. Of those 40 million, more than 20 million are performed in North America, about 1.5 million in Canada, and approximately 15,000 in southern Nevada.

GMIS is currently developing a scalable standalone system to produce the isotope, allowing for custom deployments to other areas of the country.

The five-year CRADA calls for NSTec to provide technical integration, modeling, materials, and design support to GMIS's mission.  

NSTec also brings to the CRADA a staff of nuclear and health physicists, skilled physics and electronics technicians, a variety of radiological materials, and an extensive inventory of radiation detection equipment.

For more information: www.nstec.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init